Teprotumumab reduces double vision, improves quality of life in TED
Results from the phase 3 OPTIC study showed teprotumumab (Horizon Therapeutics) significantly reduced double vision and improved quality of life in patients with active thyroid eye disease, according to data presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium.
Previous data from the OPTIC study showed that patients treated with teprotumumab had a meaningful improvement in proptosis compared with placebo (82.9% vs 9.5%, respectively)
The new data presented showed that 68% of patients on teprotumumab had an improvement from baseline of at least one grade in diplopia at week 24 compared to 29% treated with placebo.
In addition, a mean change of 13.79 on the Graves’ Ophthalmopathy Quality of Life (GO-QoL) scale was reported in patients receiving teprotumumab, compared to a change of 4.43 for patients receiving placebo.
“The Phase 3 data further illustrate the potential for teprotumumab to benefit the most prominent and challenging characteristics of active thyroid eye disease, most notably the vision impairment and subsequent detrimental effect on daily life,” said Shao-Lee Lin, MD, PhD, executive vice president, head of research and development and chief scientific officer, Horizon, in a press release. “With the findings of our Phase 3 clinical trial demonstrating benefit across all of the ranked endpoints studied, we are one step closer to addressing the unmet need in the TED community for an FDA-approved medicine.”
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809